Inhibitory Effects of SU5416, a Selective Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, on Experimental Corneal Neovascularization
Authors:
- Uğurcan KeskinUKUğurcan Keskin
- Yüksel TotanYTYüksel Totan
- Remzi KaradağRKRemzi Karadağ
- Mesut ErdurmuşMEMesut Erdurmuş
- Bahri AydınBABahri Aydın
- 21 June 2011
- journal article
- Published by S. Karger AG in Ophthalmic Research
- Vol. 47 (1) , 13-18
Abstract
Purpose: Treatment of neovascularization in ocular diseases with vascular endothelial growth factor (VEGF) inhibition shows promising results. SU5416 is a low-molecular-weight tyrosine kinase inhibitor. It selectively inhibits the membrane-bound tyrosine kinase activity of VEGF-2 receptor (Flk-1/KDR) and blocks the intracellular signaling process. The aim of this study was to evaluate the effect of SU5416 on corneal neovascularization. Methods: Corneas were cauterized with silver nitrate/potassium nitrate sticks in 20 eyes of 20 BALB/C mice. In the study group (n = 10), SU5416 (25 mg/kg) dissolved in dimethyl sulfoxide was given as an intraperitoneal injection in a single daily dose for 7 days. The other group of 10 mice given intraperitoneal dimethyl sulfoxide alone served as a control group. After 7 days, corneal neovascularization was evaluated using photographs captured by fluorescein angiography. Colored photographs were taken by a biomicroscope with a digital camera. Data were expressed as mean neovascular length and mean number of new vessels for each animal. The values were computed and compared between the groups. Results: The mean burn stimulus intensities were not different between the groups. In the study group, the mean length of the vessels and the mean number of vessels were 0.49 ± 0.05 and 11.20 ± 1.69 mm, respectively. In the control group, the mean length of the vessels and the mean number of the vessels were 0.89 ± 0.11 and 17.80 ± 1.03 mm, respectively. There is a statistically significant difference in the mean length and the mean number of new vessels between the study and control groups (p < 0.001). Conclusion: Selective inhibition of VEGFR-2 (Flk-1/KDR) tyrosine kinase with SU5416 was shown to have an inhibitory effect on corneal neovascularization in this animal model. VEGFR-2 (Flk-1/KDR) tyrosine kinase inhibition may represent a different pathway for treatment of the neovascularization process in ocular pathologies. Fluorescein angiography photographs of new vessels on the cornea may provide a better evaluation of neovascularization than colored images in animal models.Keywords
This publication has 27 references indexed in Scilit:
- Inhibitory Effects of Topical Thymoquinone on Corneal NeovascularizationCornea, 2007
- Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future DirectionsThe Oncologist, 2006
- Increased Expression of Inflammatory Cytokines and Matrix Metalloproteinases in Pseudophakic Corneal EdemaInvestigative Ophthalmology & Visual Science, 2005
- Role of angiogenesis in tumor growth and metastasisSeminars in Oncology, 2002
- Corneal neovascularizationCurrent Opinion in Ophthalmology, 2001
- Effect of caffeic acid phenethyl ester on corneal neovascularization in ratsCurrent Eye Research, 2001
- Expression of Matrix Metalloproteinase-2 (MMP-2) and Vascular Endothelial Growth Factor (VEGF) in Inflammation-associated Corneal NeovascularizationExperimental Eye Research, 2000
- Induction of macrophage inflammatory protein-1α and vascular endothelial growth factor during inflammatory neovascularization in the mouse corneaAngiogenesis, 1999
- Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularizationJournal of Clinical Investigation, 1999
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995